Brief Title
Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Official Title
Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Brief Summary
Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis. The aim of this study is to assess the percentage of patients who use cannabis to better relieve their pain or anxiety in chronic inflammatory rheumatism.
Detailed Description
Thanks to a better understanding of the pathophysiological mechanisms of inflammatory rheumatism, rheumatology has known for several decades a growth in its therapeutic arsenal (csDMARDs, bDMARDs, tDMARDs). rheumatism control has thus been optimized. however, patients very often keep pain, anxiety, residual fatigue, poorly controlled by our conventional therapies. patients then turn to non-drug therapies, among which the use of cannabis. endocannabinoids have an analgesic and anti-inflammatory action recognized in pre-clinical trials. however, investigators currently lack the data to authorize its use in clinical rheumatology. the aim of this study is to determine the prevalence of cannabis users in patients with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in our unit. as a second intention, investigators will refine the consumption characteristics. Investigators will also look for possible risk factors for consumption (sensitivity to pain, catastrophism, standard of living, anxiety, depression, rheumatic activity and quality of life).
Study Type
Observational
Primary Outcome
prevalence of cannabis use in patients with chronic inflammatory rheumatic conditions
Secondary Outcome
Percentage of patients with problematic cannabis use
Condition
Rheumatoid Arthritis
Intervention
Cannabis questionnaire
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Behavioral
Estimated Enrollment
501
Start Date
May 19, 2020
Completion Date
March 19, 2021
Primary Completion Date
March 19, 2021
Eligibility Criteria
Inclusion Criteria: - Rheumatoid Arthritis (ACR 2010 Criteria) - Ankylosing Spondylitis (New york or ASAS criteria) - Psoriatic Arthritis (CASPAR criteria) Exclusion Criteria: - Patient unable to complete questionnaires or unable to express informed consent - Guardianship, trusteeship, deprivation of liberties, safeguard of justice
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Sylvain Mathieu, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT04402554
Organization ID
RNI 2020 MATHIEU
Secondary IDs
2020-A00473-36
Responsible Party
Sponsor
Study Sponsor
University Hospital, Clermont-Ferrand
Study Sponsor
Sylvain Mathieu, Principal Investigator, University Hospital, Clermont-Ferrand
Verification Date
June 2021